San Diego, California, Stockholm, Sweden, February 28, 2018 – IRRAS (NASDAQ STOCKHOLM: IRRAS), a commercial-stage medical technology company developing breakthrough devices for a broad range of intracranial bleeding applications and procedures, today announced the appointment of Kellie Fontes as Senior Director, Human Capital and a member of the executive management team. Ms Fontes brings nearly 30 years of experience and knowledge in all facets of Human Resources. Ms Fontes will report directly to the President CEO of IRRAS, Kleanthis G. Xanthopoulos, Ph.D., from the San Diego site in California.
“I am very pleased to welcome Kellie to the executive team of IRRAS,” said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of IRRAS. “Kellie’s results-oriented HR skills and recognized focus on the creation of strong teams will be of great value to IRRAS as we continue to build a leading, global medical technology company focus on the treatment of intracranial bleedings.”
Ms. Fontes commented, “Working within the medical technology sector, helping patients in need and being part of creating the solutions of tomorrow, is extremely exciting to me. I am very pleased to join the team of IRRAS and to strengthen the strategic work of talent management and HR compliance.”
Ms. Fontes has a vast experience of Human Resources within the pharmaceutical and high-technology industries and brings in-depth knowledge of HR compliance and risk management. She is recognized for her strong skills in developing strategies to strengthen compliance and mitigate risk as well as driving change and facilitating the creation of strong teams. She has led extensive coaching of senior leaders on building personal capabilities and execution of business strategy. Most recently, she acted as Employee Relations and Compliance Director at the high-technology systems company General Atomics. Prior to General Atomics, she held several leading HR positions for nearly ten years at GlaxoSmithKline and acted as a US Director. She holds a BSc in Speech Communication from Montana State University.
About IRRAflow™
IRRAS has developed and commercialized a revolutionary intelligent brain fluid management device stemming from its core IRRAflow technology that addresses the complications associated with the occurrence of intracranial bleedings. Currently available devices do not address the complications that lead to death because they do not prevent occlusion (or blockage) in the catheter during treatment and they do not accurately monitor intracranial pressure (ICP). IRRAS’ products provide a transformative solution for stroke and hematoma patients with less invasiveness and more efficacy, through the integration of aspiration, targeted infusion and intracranial pressure monitoring in a single robust device.
About IRRAS AB
IRRAS AB (NASDAQ Stockholm: IRRAS), is a publicly-traded, commercial-stage medical technology company focused on designing, developing and commercializing innovative solutions for various brain pathologies, with a goal of dramatically improving patient outcomes, reducing patient-time in the intensive care unit and medical ward, and providing significant health economic benefits to hospitals and healthcare providers. The Company’s initial product focus is on intracranial fluid management solutions that utilize its proprietary platform technology, IRRAflow, which is a CE-marked, fully integrated, closed-circuit medical device system that enables intelligent intracranial fluid management as well as accurate, real-time monitoring of intracranial pressure.
With its unique product portfolio, protected by key intellectual property patents and patent applications, IRRAS is well-positioned to improve patient outcomes and establish a leadership position in the medical device market. IRRAS maintains its headquarters in Sweden with corporate offices in Germany and San Diego, CA, USA. For more information, please visit www.irras.com.
Investor and Media Contact:
Fredrik Alpsten
CFO and Deputy CEO
+46 706 67 31 06
fredrik.alpsten@irras.com
This information is information that IRRAS is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person above, on February 28, 2018 at 08.00 a.m. (CET).
